METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1
Cancer Letters · 2025-02 · 611 · 217194
DOI: 10.1016/j.canlet.2024.217194 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-02. Verfasst von Xianfu Wei und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China; State Key Laboratory …. Hauptthemen laut MEDLINE: Osteosarcoma, Drug Resistance, Neoplasm, Phosphopyruvate Hydratase, Tumor Suppressor Proteins. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Chemoresistance remains the main obstacle limiting the treatment of osteosarcoma, seriously affecting the prognosis of adolescent patients with osteosarcoma. Recently, long non-coding RNAs (lncRNAs) were reported to be involved in chemoresistance, while the mechanisms of lncRNAs underlying osteosarcoma resistance to chemotherapy remain elusive. Here, LINC00520 was identified as a novel cisplatin resistance-related lncRNA in osteosarcoma, and its high expression was associated with poor prognosis of osteosarcoma patients. Functionally, LINC00520 could potentiate osteosarcoma resistance to cisplatin in vitro and in vivo. Mechanistically, LINC00520 bound to ENO1 and upregulated ENO1 protein expression by blocking FBXW7-mediated ENO1 ubiquitination and proteasomal degradation, thereby promoting glycolysis and ultimately inducing cisplatin resistance in osteosarcoma. Furthermore, METTL3 could stabilize and upregulate LINC00520 in an m6A-YTHDF2-dependent manner in osteosarcoma. This study proposes a novel lncRNA-driven mechanism for cisplatin resistance in osteosarcoma, and offers a promising therapeutic strategy for reversing chemoresistance in osteosarcoma by targeting the METTL3/LINC00520/ENO1/glycolysis axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China; State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Nati…
Zitieren
APA
Wei, X., Feng, J., Chen, L., Zhang, C., Liu, Y., Zhang, Y., Xu, Y., Zhang, J., Wang, J., Yang, H., Han, X., & Wang, G. (2025). METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1. Cancer Letters, 611, 217194. https://doi.org/10.1016/j.canlet.2024.217194
Vancouver
Wei X, Feng J, Chen L, Zhang C, Liu Y, Zhang Y, et al. METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1. Cancer Letters. 2025;611:217194. doi:10.1016/j.canlet.2024.217194
BibTeX
@article{Wei2025,
author = {Wei, Xianfu and Feng, Jinyan and Chen, Long and Zhang, Chao and Liu, Yongheng and Zhang, Yan and Xu, Yao and Zhang, Jin and Wang, Jinwu and Yang, Houzhi and Han, Xiuxin and Wang, Guowen},
title = {METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1},
journal = {Cancer Letters},
year = {2025},
volume = {611},
pages = {217194},
doi = {10.1016/j.canlet.2024.217194}
}
EUVIMED